Open Source Securities released a research report on April 25 stating that it gave Hongbo Pharmaceutical (301230.SZ) a purchase rating. The main reasons for the rating include: 1) steady overall revenue growth, with short-term profit fluctuations due to falling prices of core API products; 2) steady development of the drug discovery business, with the CAD/AIDD platform continuing to empower customer new drug projects; 3) continuing to increase marketing and promotion efforts, and the expected rapid release of core API products. (Mainichi Keizai Shimbun)
开源证券4月25日发布研报称，给予泓博医药（301230.SZ）买入评级。评级理由主要包括：1）收入端整体稳健增长，核心原料药产品价格下滑导致利润短期波动；2）药物发现业务稳健发展，CADD/AIDD平台持续赋能客户新药项目；3）持续加大市场营销及推广力度，核心原料药产品有望快速放量。（每日经济新闻）
Open Source Securities released a research report on April 25 stating that it gave Hongbo Pharmaceutical (301230.SZ) a purchase rating. The main reasons for the rating include: 1) steady overall revenue growth, with short-term profit fluctuations due to f
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.